依普沙坦治疗不稳定型心绞痛的疗效观察

Efficacy and Safety of Eprosartan for Unstable Angina Pectoris

目的:探讨依普沙坦治疗不稳定型心绞痛(UAP)的疗效及安全性。方法:选择UAP患者80例,按随机数字表法分为观察组和对照组,每组40例。对照组患者给予硝酸酯类药物、阿司匹林、β-受体阻滞剂及他汀类药物等常规用药治疗;观察组患者在常规治疗的基础上给予依普沙坦600 mg,1次/d,连续服药6个月。观察两组患者用药前、用药后6个月的临床疗效,心电图ST段变化,血压水平及血清内皮素(ET)、一氧化氮(NO)水平改变,左室肥厚的逆转及舒张功能指标改善等情况。结果:两组患者治疗6个月后,心绞痛临床疗效、心电图ST段变化、血清ET和NO水平改变、左室肥厚逆转及舒张功能指标改善程度与用药前比较差异均有统计学意义(P<0.05),且观察组明显优于对照组(P<0.05)。两组患者治疗、后血压均较治疗前明显下降(P<0.05);但组间比较差异无统计学意义(P>0.05)。结论:依普沙坦治疗不稳定型心绞痛疗效确切且安全。

OBJECTIVE： To evaluate the efficacy and safety of eprosartan for unstable angina pectoris. METHODS： 80 patients with unstable angina pectoris were randomly assigned to receive conventional medications alone including nitrates, aspirin, [3-blockers and statins （control group ） or in combination with eprosartan 600 mg q. d for six consecutive months （trial group）. The clinical efficacy, ST segment change, blood pressure, serum ET and NO levels, reversal of left ventricular hypertrophy and improvement in diastolic function parameters at 6 months were followed.RESULTS： After treatment of 6 months, significant differences were noted for both groups as compared with before treatment in clinical efficacy for angina pectoris, ST-segment change, serum levels of ET and NO, reversal of left ventricular hypertrophy and improvement in diastolic function parameters { P 〈 0. 05）, with the trial group showing better improvement than in the control group （P 〈 0. 05）. The blood pressure in both group reduced after treatment compared with before treatment （P 〈0. 05）, however, the difference was not statistically significant between the two groups （P 〉 0. 05）. CONCLUSIONS. Eprosartan was proved to be safe and effective for unstable angina pectoris.